Statins and the Joint: Multiple Targets for a Global Protection?

Seminars in Arthritis and Rheumatism

Volumn 40, Issue 5, 2011, Pages 430-446

  Lazzerini, Pietro Enea ^a   Capecchi, Pier Leopoldo ^a   Selvi, Enrico ^a   Lorenzini, Sauro ^a   Bisogno, Stefania ^a   Baldari, Cosima Tatiana ^a   Galeazzi, Mauro ^a   Laghi Pasini, Franco ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Cartilage; Inflammatory arthritis; Joint; Osteoarthritis; Rheumatoid arthritis; Statins; Subchondral bone; Synovium

Indexed keywords

ATORVASTATIN; CERIVASTATIN; COMPACTIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTHROPATHY; ARTICLE; ARTICULAR CARTILAGE; BONE PLATE; CHRONIC ARTHRITIS; CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG TRANSPORT; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INTERVERTEBRAL DISK DEGENERATION; MEDLINE; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTECTION; PROTEIN SYNTHESIS INHIBITION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIUM; SYSTEMATIC REVIEW;

ANIMALS; BONE AND BONES; CARTILAGE, ARTICULAR; DISEASE MODELS, ANIMAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JOINT DISEASES; RETROSPECTIVE STUDIES; SYNOVIAL MEMBRANE; TREATMENT OUTCOME;

EID: 79953050609     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2010.06.010     Document Type: Article

References (89)

1. Wierzbicki A.S., Poston R., Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther 2003, 99:95-112.
2. Bhatnagar D., Soran H., Durrington P.N. Hypercholesterolaemia and its management. BMJ 2008, 337:a993. 10.1136/bmj.a993.
3. Corsini A., Bellosta S., Baetta R., Fumagalli R., Paoletti R., Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999, 84:413-428.
4. Ghittoni R., Lazzerini P.E., Laghi-Pasini F., Baldari C.T. T lymphocytes as targets of statins: molecular mechanisms and therapeutic perspectives. Inflamm Allergy Drug Targets 2007, 6:3-16.
5. Ghittoni R., Patrussi L., Pirozzi K., Pellegrini M., Lazzerini P.E., Capecchi P.L., et al. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. FASEB J 2005, 19:605-607.
6. Ghittoni R., Napolitani G., Benati D., Ulivieri C., Patrussi L., Laghi-Pasini F., et al. Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases. Eur J Immunol 2006, 36:2885-2893.
7. Halcox J.P., Deanfield J.E. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 2004, 109:II42-II48.
8. Gardner D.L. Problems and paradigms in joint pathology. J Anat 1994, 184:465-476.
9. Tarner I.H., Härle P., Müller-Ladner U., Gay R.E., Gay S. The different stages of synovitis: acute vs chronic, early vs late and non-erosive vs erosive. Best Pract Res Clin Rheumatol 2005, 19:19-35.
10. Leung B.P., Sattar N., Crilly A., Prach M., McCarey D.W., Payne H., et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003, 170:1524-1530.
11. Yokota K., Miyazaki T., Hirano M., Akiyama Y., Mimura T. Simvastatin inhibits production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Rheumatol 2006, 33:463-471.
12. Lazzerini P.E., Lorenzini S., Selvi E., Capecchi P.L., Chindamo D., Bisogno S., et al. Simvastatin inhibits cytokine production and nuclear factor-kB activation in interleukin 1beta-stimulated synoviocytes from rheumatoid arthritis patients. Clin Exp Rheumatol 2007, 25:696-700.
13. Blaschke S., Viereck V., Schwarz G., Klinger H.M., Guerluek S., Muller G.A. Anti-inflammatory effects of atorvastatin on peripheral blood mononuclear cells and synovial fibroblasts in rheumatoid arthritis. Scand J Rheumatol 2009, 26:1-5.
14. Xu H., Liu P., Liang L., Danesh F.R., Yang X., Ye Y., et al. RhoA-mediated, tumor necrosis factor alpha-induced activation of NF-kappaB in rheumatoid synoviocytes: inhibitory effect of simvastatin. Arthritis Rheum 2006, 54:3441-3451.
15. Nagashima T., Okazaki H., Yudoh K., Matsuno H., Minota S. Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis. Arthritis Rheum 2006, 54:579-586.
16. Connor A.M., Berger S., Narendran A., Keystone E.C. Inhibition of protein geranylgeranylation induces apoptosis in synovial fibroblasts. Arthritis Res Ther 2006, 8:R94.
17. Yokota K., Miyoshi F., Miyazaki T., Sato K., Yoshida Y., Asanuma Y., et al. High concentration simvastatin induces apoptosis in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Rheumatol 2008, 35:193-200.
18. Litinsky I., Golan I., Yaron M., Yaron I., Caspi D., Elkayam O. Simvastatin induces apoptosis of fibroblast-like synoviocytes. Open Rheumatol J 2009, 3:35-40.
19. Mistafa O., Stenius U. Statins inhibit Akt/PKB signalling via P2X7 receptor in pancreatic cancer cells. Biochem Pharmacol 2009, 78:1115-1126.
20. Caporali F., Capecchi P.L., Gamberucci A., Lazzerini P.E., Pompella G., Natale M., et al. Human rheumatoid synoviocytes express functional P2X7 receptors. J Mol Med 2008, 86:937-949.
21. Kawahito Y., Kondo M., Tsubouchi Y., Hashiramoto A., Bishop-Bailey D., Inoue K., et al. 15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 2000, 106:189-197.
22. Matsuno H., Yudoh K., Nakazawa F., Sawai T., Uzuki M., Nishioka K., et al. Antirheumatic effects of humanized anti-Fas monoclonal antibody in human rheumatoid arthritis/SCID mouse chimera. J Rheumatol 2002, 29:1609-1614.
23. Hegen M., Keith J.C., Collins M., Nickerson-Nutter C.L. Utility of animal models for identification of potential therapeutics for rheumatoid arthritis. Ann Rheum Dis 2008, 67:1505-1515.
24. Funk J.L., Chen J., Downey K.J., Clark R.A. Bone protective effect of simvastatin in experimental arthritis. J Rheumatol 2008, 35:1083-1091.
25. Barsante M.M., Roffê E., Yokoro C.M., Tafuri W.L., Souza D.G., Pinho V., et al. Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis. Eur J Pharmacol 2005, 516:282-289.
26. Wahane V.D., Kumar V.L. Atorvastatin ameliorates inflammatory hyperalgesia in rat model of monoarticular arthritis. Pharmacol Res 2010, 61:329-333.
27. Yamagata T., Kinoshita K., Nozaki Y., Sugiyama M., Ikoma S., Funauchi M. Effects of pravastatin in murine collagen-induced arthritis. Rheumatol Int 2007, 27:631-639.
28. Ho P.P., Higgins J.P., Kidd B.A., Tomooka B., Digennaro C., Lee L.Y., et al. Tolerizing DNA vaccines for autoimmune arthritis. Autoimmunity 2006, 39:675-682.
29. Charles-Schoeman C., Banquerigo M.L., Hama S., Navab M., Park G.S., Van Lenten B.J., et al. Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis. Clin Immunol 2008, 127:234-244.
30. Palmer G., Chobaz V., Talabot-Ayer D., Taylor S., So A., Gabay C., et al. Assessment of the efficacy of different statins in murine collagen-induced arthritis. Arthritis Rheum 2004, 50:4051-4059.
31. Kanda H., Hamasaki K., Kubo K., Tateishi S., Yonezumi A., Kanda Y., et al. Antiinflammatory effect of simvastatin in patients with rheumatoid arthritis. J Rheumatol 2002, 29:2024-2026.
32. Abud-Mendoza C., de la Fuente H., Cuevas-Orta E., Baranda L., Cruz-Rizo J., González-Amaro R. Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 2003, 12:607-611.
33. McCarey D.W., McInnes I.B., Madhok R., Hampson R., Scherbakov O., Ford I., et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004, 363:2015-2021.
34. Mäki-Petäjä K.M., Booth A.D., Hall F.C., Wallace S.M., Brown J., McEniery C.M., et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 2007, 50:852-858.
35. Shirinsky I.V., Zheltova O.I., Solovyova N.Y., Kozlov V.A., Shirinsky V.S. Changes in disease activity, cytokine production, and proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis after simvastatin treatment. Scand J Rheumatol 2009, 38:23-27.
36. Tikiz C., Utuk O., Pirildar T., Bayturan O., Bayindir P., Taneli F., et al. Effects of angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with long-term rheumatoid arthritis. J Rheumatol 2005, 32:2095-3101.
37. Charles-Schoeman C., Khanna D., Furst D.E., McMahon M., Reddy S.T., Fogelman A.M., et al. Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol 2007, 34:1459-1464.
38. Okamoto H., Koizumi K., Kamitsuji S., Inoue E., Hara M., Tomatsu T., et al. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J Rheumatol 2007, 34:964-968.
39. van Denderen J.C., Peters M.J., van Halm V.P., van der Horst-Bruinsma I.E., Dijkmans B.A., et al. Statin therapy might be beneficial for patients with ankylosing spondylitis. Ann Rheum Dis 2006, 65:695-696.
40. Nurmohamed M.T., Dijkmans B.A. Dyslipidaemia, statins and rheumatoid arthritis. Ann Rheum Dis 2009, 68:453-455.
41. Li D., Mehta J.L. Oxidized LDL, a critical factor in atherogenesis. Cardiovasc Res 2005, 68:353-354.
42. Ansell B.J. Targeting the anti-inflammatory effects of high-density lipoprotein. Am J Cardiol 2007, 100:n3-n9.
43. van Halm V.P., Nielen M.M., Nurmohamed M.T., van Schaardenburg D., Reesink H.W., Voskuyl A.E., et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007, 66:184-188.
44. Jick S.S., Choi H., Li L., McInnes I.B., Sattar N. Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis. Ann Rheum Dis 2009, 68:546-551.
45. Goldring M.B., Marcu K.B. Cartilage homeostasis in health and rheumatic diseases. Arthritis Res Ther 2009, 11:224.
46. Hatano H., Maruo A., Bolander M.E., Sarkar G. Statin stimulates bone morphogenetic protein-2, aggrecan, and type 2 collagen gene expression and proteoglycan synthesis in rat chondrocytes. J Orthop Sci 2003, 8:842-848.
47. Zhang H., Lin C.Y. Simvastatin stimulates chondrogenic phenotype of intervertebral disc cells partially through BMP-2 pathway. Spine 2008, 33:E525-E531.
48. Lazzerini P.E., Capecchi P.L., Nerucci F., Fioravanti A., Chellini F., Piccini M., et al. Simvastatin reduces MMP-3 level in interleukin 1beta stimulated human chondrocyte culture. Ann Rheum Dis 2004, 63:867-869.
49. Dombrecht E.J., De Tollenaere C.B., Aerts K., Cos P., Schuerwegh A.J., Bridts C.H., et al. Antioxidant effect of bisphosphonates and simvastatin on chondrocyte lipid peroxidation. Biochem Biophys Res Commun 2006, 348:459-464.
50. Dombrecht E.J., Van Offel J.F., Bridts C.H., Ebo D.G., Seynhaeve V., Schuerwegh A.J., et al. Influence of simvastatin on the production of pro-inflammatory cytokines and nitric oxide by activated human chondrocytes. Clin Exp Rheumatol 2007, 25:534-539.
51. Simopoulou T., Malizos K.N., Poultsides L., Tsezou A. Protective effect of atorvastatin in cultured osteoarthritic chondrocytes. J Orthop Res 2010, 20:110-115.
52. Akasaki Y., Matsuda S., Nakayama K., Fukagawa S., Miura H., Iwamoto Y. Mevastatin reduces cartilage degradation in rabbit experimental osteoarthritis through inhibition of synovial inflammation. Osteoarthritis Cartilage 2009, 17:235-243.
53. Zhang H., Wang L., Park J.B., Park P., Yang V.C., Hollister S.J., et al. Intradiscal injection of simvastatin retards progression of intervertebral disc degeneration induced by stab injury. Arthritis Res Ther 2009, 11:R172.
54. Beattie M.S., Lane N.E., Hung Y.Y., Nevitt M.C. Association of statin use and development and progression of hip osteoarthritis in elderly women. J Rheumatol 2005, 32:106-110.
55. Karsdal M.A., Leeming D.J., Dam E.B., Henriksen K., Alexandersen P., Pastoureau P., et al. Should subchondral bone turnover be targeted when treating osteoarthritis?. Osteoarthritis Cartilage 2008, 16:638-646.
56. Verbruggen G., Wittoek R., Groeneboer S., Cruyssen B.V., Goemaere S., Elewaut D. Osteochondral repair in synovial joints. Curr Opin Rheumatol 2007, 19:265-271.
57. Calvo E., Castañeda S., Largo R., Fernández-Valle M.E., Rodríguez-Salvanés F., Herrero-Beaumont G. Osteoporosis increases the severity of cartilage damage in an experimental model of osteoarthritis in rabbits. Osteoarthritis Cartilage 2007, 15:69-77.
58. Schett G., Teitelbaum S.L. Osteoclasts and arthritis. J Bone Miner Res 2009, 24:1142-1146.
59. Kaji H., Kanatani M., Sugimoto T., Chihara K. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures. Horm Metab Res 2005, 37:589-592.
60. Grasser W.A., Baumann A.P., Petras S.F., Harwood H.J., Devalaraja R., Renkiewicz R., et al. Regulation of osteoclast differentiation by statins. J Musculoskelet Neuronal Interact 2003, 3:53-62.
61. Fisher J.E., Rogers M.J., Halasy J.M., Luckman S.P., Hughes D.E., Masarachia P.J., et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A 1999, 96:133-138.
62. Hughes A., Rogers M.J., Idris A.I., Crockett J.C. A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo. Calcif Tissue Int 2007, 81:403-413.
63. Woo J.T., Nakagawa H., Krecic A.M., Nagai K., Hamilton A.D., Sebti S.M., et al. Inhibitory effects of mevastatin and a geranylgeranyl transferase I inhibitor (GGTI-2166) on mononuclear osteoclast formation induced by receptor activator of NF kappa B ligand (RANKL) or tumor necrosis factor-alpha (TNF-alpha). Biochem Pharmacol 2005, 69:87-95.
64. Woo J.T., Kasai S., Stern P.H., Nagai K. Compactin suppresses bone resorption by inhibiting the fusion of prefusion osteoclasts and disrupting the actin ring in osteoclasts. J Bone Miner Res 2000, 15:650-662.
65. Woo J.T., Yonezawa T., Cha B.Y., Teruya T., Nagai K. Pharmacological topics of bone metabolism: antiresorptive microbial compounds that inhibit osteoclast differentiation, function, and survival. J Pharmacol Sci 2008, 106:547-554.
66. Mundy G., Garrett R., Harris S., Chan J., Chen D., Rossini G., et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999, 286:1946-1949.
67. Sugiyama M., Kodama T., Konishi K., Abe K., Asami S., Oikawa S. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun 2000, 271:688-692.
68. Ohnaka K., Shimoda S., Nawata H., Shimokawa H., Kaibuchi K., Iwamoto Y., et al. Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem Biophys Res Commun 2001, 287:337-342.
69. Maeda T., Matsunuma A., Kawane T., Horiuchi N. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun 2001, 280:874-877.
70. Ruiz-Gaspa S., Nogues X., Enjuanes A., Monllau J.C., Blanch J., Carreras R., et al. Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures. J Cell Biochem 2007, 101:1430-1438.
71. Maeda T., Matsunuma A., Kurahashi I., Yanagawa T., Yoshida H., Horiuchi N. Induction of osteoblast differentiation indices by statins in MC3T3-E1 cells. J Cell Biochem 2004, 92:458-471.
72. Viereck V., Gründker C., Blaschke S., Frosch K.H., Schoppet M., Emons G., et al. Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts. J Cell Biochem 2005, 96:1244-1253.
73. Li B., Aspden R.M. Mechanical and material properties of the subchondral bone plate from the femoral head of patients with osteoarthritis or osteoporosis. Ann Rheum Dis 1997, 56:247-254.
74. Ding M., Danielsen C.C., Hvid I. Bone density does not reflect mechanical properties in early-stage arthrosis. Acta Orthop Scand 2001, 72:181-185.
75. Ding M., Odgaard A., Hvid I. Changes in the three-dimensional microstructure of human tibial cancellous bone in early osteoarthritis. J Bone Joint Surg Br 2003, 85:906-912.
76. Bailey A.J., Sims T.J., Knott L. Phenotypic expression of osteoblast collagen in osteoarthritic bone: production of type I homotrimer. Int J Biochem Cell Biol 2002, 34:176-182.
77. Sanchez C., Deberg M.A., Bellahcène A., Castronovo V., Msika P., Delcour J.P., et al. Phenotypic characterization of osteoblasts from the sclerotic zones of osteoarthritic subchondral bone. Arthritis Rheum 2008, 58:442-455. Erratum in: Arthritis Rheum 2008;58:887.
78. Couchourel D., Aubry I., Delalandre A., Lavigne M., Martel-Pelletier J., Pelletier J.P., et al. Altered mineralization of human osteoarthritic osteoblasts is attributable to abnormal type I collagen production. Arthritis Rheum 2009, 60:1438-1450.
79. Horiuchi N., Maeda T. Statins and bone metabolism. Oral Dis 2006, 12:85-101.
80. Hughes A., Rogers M.J., Idris A.I., Crockett J.C. A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo. Calcif Tissue Int 2007, 81:403-413.
81. Uyar Y., Baytur Y., Inceboz U., Demir B.C., Gumuser G., Ozbilgin K. Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats. Maturitas 2009, 63:261-267.
82. Ho M.L., Chen Y.H., Liao H.J., Chen C.H., Hung S.H., Lee M.J., et al. Simvastatin increases osteoblasts and osteogenic proteins in ovariectomized rats. Eur J Clin Invest 2009, 39:296-303.
83. Jadhav S.B., Jain G.K. Statins and osteoporosis: new role for old drugs. J Pharm Pharmacol 2006, 58:3-18.
84. Jadhav S.B., Narayana Murthy P.S., Singh M.M., Jain G.K. Distribution of lovastatin to bone and its effect on bone turnover in rats. J Pharm Pharmacol 2006, 58:1451-1458.
85. Gutierrez G.E., Lalka D., Garrett I.R., Rossini G., Mundy G.R. Transdermal application of lovastatin to rats causes profound increases in bone formation and plasma concentrations. Osteoporos Int 2006, 17:1033-1042.
86. Ridker P.M., Solomon D.H. Should patients with rheumatoid arthritis receive statin therapy. Arthritis Rheum 2009, 60:1205-1209.
87. Conaghan P.G., Vanharanta H., Dieppe P.A. Is progressive osteoarthritis an atheromatous vascular diseases?. Ann Rheum Dis 2005, 64:1539-1541.
88. Bansback N., Ara R., Ward S., Anis A., Choi H.K. Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis. Pharmacoeconomics 2009, 27:25-37.
89. Toms T.E., Panoulas V.F., Douglas K.M., Griffiths H., Sattar N., Smith J.P., et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?. Ann Rheum Dis 2010, 69:683-688.